Literature DB >> 10608484

Correlation between high intake of glycyrrhizin and myolysis of the papillary muscles: an experimental in vivo study.

T Rossi1, R A Fano, M Castelli, M Malagoli, A I Ruberto, G Baggio, R Zennaro, M Migaldi, G Barbolini.   

Abstract

The ingestion of large quantities of glycyrrhizin, whether as a drug or a sweetener, is known, in susceptible subjects, to induce a syndrome similar to hypermineralcorticoidism, with bouts of hypertension, hypokaliaemia and rabdomyolysis, sometimes associated with severe renal failure and hypokaliaemia-induced arrythmias. Glycyrrhizin is also known to isomerize into the glycyrrhetic (or glycyrrhetinic) acids 18alpha- and 18beta-. In previous works, we reported that these metabolites cause bouts of hypertension and reduction in diuresis at low doses in the rat. In particular, the alpha isomer causes significant elimination of the calcium ion in the urine. The present findings confirm that 18alpha-glycyrrhetic acid is more toxic than either glycyrrhizin or the beta isomer. Histopathological study of tissue samples taken from rats treated with the alpha isomer also reveal selective damage to the myocardium with oedema, myolysis, apoptosis and blistering of the sarcoplasm. These effects begin to appear in the course of subchronic treatment, they manifest themselves in acute treatment and correlate closely with the electrocardiographic changes recorded in rats acutely treated with 18alpha-glycyrrhetic acid.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10608484     DOI: 10.1111/j.1600-0773.1999.tb02012.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  1 in total

1.  Glycyrrhizic acid can attenuate metabolic deviations caused by a high-sucrose diet without causing water retention in male Sprague-Dawley rats.

Authors:  Hamish Alexander Fernando; Chanchal Chandramouli; Dayang Rosli; Yi Lyn Lam; Sheau Ting Yong; Hui Ping Yaw; So Ha Ton; Khalid Abdul Kadir; Amanda Sainsbury
Journal:  Nutrients       Date:  2014-11-04       Impact factor: 5.717

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.